Arlinda Lee
Stock Analyst at Canaccord Genuity
(2.19)
# 2,742
Out of 4,893 analysts
46
Total ratings
43.48%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $12.56 | +67.20% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $600 → $300 | $1.56 | +19,130.77% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $375 → $90 | $25.05 | +259.28% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $88.80 | -59.46% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $13.62 | +267.11% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $58.76 | +172.29% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $8.07 | +395.66% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $31.38 | +234.61% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $57.63 | -53.15% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $129.34 | -22.68% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.73 | +1,731.50% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $270 | $4.84 | +5,478.51% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.14 | +13,935.09% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $12.56
Upside: +67.20%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $600 → $300
Current: $1.56
Upside: +19,130.77%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $375 → $90
Current: $25.05
Upside: +259.28%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $88.80
Upside: -59.46%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $13.62
Upside: +267.11%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $58.76
Upside: +172.29%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $8.07
Upside: +395.66%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $31.38
Upside: +234.61%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $57.63
Upside: -53.15%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $129.34
Upside: -22.68%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.73
Upside: +1,731.50%
Nov 5, 2019
Maintains: Buy
Price Target: $225 → $270
Current: $4.84
Upside: +5,478.51%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.14
Upside: +13,935.09%